Physician profile
Ishwaria Subbiah
NPI 1124283213
$9,594.84
in general payments reported to CMS, 2019-2025
8 companies · $355 in 2025
The $355 reported for 2025 was more than what 88% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,000 · 2023: $2,845 · 2024: $4,395 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,823 · Travel and Lodging: $1,029 · Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,822.50 |
| Travel and Lodging | $1,029.13 |
| Food and Beverage | $743.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,284.44 | 2023-2025 | Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $2,000.00 | 2022 | |
| Pfizer INC. | $150.00 | 2025 | |
| Deciphera Pharmaceuticals INC. | $50.24 | 2024 | Qinlock |
| Blueprint Medicines Corporation | $32.00 | 2024 | Ayvakit |
| Tempus Ai, INC | $29.56 | 2024 | |
| Astellas Pharma US INC | $25.18 | 2025 | Xtandi |
| Springworks Therapeutics, INC. | $23.42 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishwaria Subbiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.